These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 31346605)

  • 1. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
    Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
    Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy.
    Chen J; Wei J; Xia P; Liu Y; Belew MD; Toohill R; Wu BJ; Cheng Z
    Cardiovasc Res; 2024 Jul; 120(9):1024-1036. PubMed ID: 38646672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
    Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
    Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
    Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
    Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity.
    Gioffré S; Ricci V; Vavassori C; Ruggeri C; Chiesa M; Alfieri I; Zorzan S; Buzzetti M; Milano G; Scopece A; Castiglioni L; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
    Biomed Pharmacother; 2019 Feb; 110():1-8. PubMed ID: 30453253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice.
    Stark C; Taimen P; Savunen T; Koskenvuo J
    BMC Res Notes; 2018 Feb; 11(1):148. PubMed ID: 29467032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
    Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
    Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model.
    Razmaraii N; Babaei H; Mohajjel Nayebi A; Asadnasab G; Ashrafi Helan J; Azarmi Y
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):237-45. PubMed ID: 26544684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
    Liu G; Liu Y; Wang R; Hou T; Chen C; Zheng S; Dong Z
    Cardiovasc Ther; 2016 Aug; 34(4):216-24. PubMed ID: 27097055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.
    Bai Y; Chen Q; Sun YP; Wang X; Lv L; Zhang LP; Liu JS; Zhao S; Wang XL
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of cardiomyopathy induced by doxorubicin in rats.
    Medeiros-Lima DJM; Carvalho JJ; Tibirica E; Borges JP; Matsuura C
    Pharmacol Rep; 2019 Aug; 71(4):583-590. PubMed ID: 31174019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
    Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
    Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bach1/HO-1 pathway regulates oxidative stress and contributes to ferroptosis in doxorubicin-induced cardiomyopathy in H9c2 cells and mice.
    Wang Y; Qiu J; Yan H; Zhang N; Gao S; Xu N; Wang C; Lou H
    Arch Toxicol; 2024 Jun; 98(6):1781-1794. PubMed ID: 38573338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.
    McLaughlin D; Zhao Y; O'Neill KM; Edgar KS; Dunne PD; Kearney AM; Grieve DJ; McDermott BJ
    Br J Pharmacol; 2017 Nov; 174(21):3677-3695. PubMed ID: 28261787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).
    Cai C; Lothstein L; Morrison RR; Hofmann PA
    J Pharmacol Exp Ther; 2010 Oct; 335(1):223-30. PubMed ID: 20668052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
    Koka S; Das A; Zhu SG; Durrant D; Xi L; Kukreja RC
    J Pharmacol Exp Ther; 2010 Sep; 334(3):1023-30. PubMed ID: 20543097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant low-dose doxorubicin treatment and exercise.
    Sturgeon K; Schadler K; Muthukumaran G; Ding D; Bajulaiye A; Thomas NJ; Ferrari V; Ryeom S; Libonati JR
    Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R685-92. PubMed ID: 25009215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.